RTX vs TMO: Which Is the Better Buy?
Side-by-side comparison of RTX Corporation and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
RTX Corporation · Industrials
$172.90
-21.3% upside to fair value
Grade D
VS
Thermo Fisher Scientific Inc. · Healthcare
$462.60
+10.1% upside to fair value
Grade B
QuantHub Verdict
TMO has more upside to fair value
(+10.1%).
TMO trades at a lower forward P/E
(25.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
RTX |
TMO |
| Current Price |
$172.90 |
$462.60 |
| Fair Value Estimate |
$136.05 |
$509.20 |
| Upside to Fair Value |
-21.3%
|
+10.1%
|
| Market Cap |
$232.8B |
$171.9B |
| Forward P/E |
32.1x
|
25.1x
|
| EV / EBITDA |
19.2x
|
19.0x
|
| Price / Sales |
2.6x
|
3.8x
|
| Price / FCF |
27.9x
|
25.5x
|
| Revenue Growth YoY |
+8.7%
|
+6.2%
|
| Gross Margin |
20.2%
|
39.4%
|
| Operating Margin |
10.4%
|
17.8%
|
| Return on Equity |
11.2%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.59%
|
3.92%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
RTX Corporation is a leading aerospace and defense company with a diversified portfolio spanning Pratt & Whitney jet engines, Collins Aerospace avionics, and Raytheon Intelligence & Space defense systems. The company benefits from a strong competitive moat supported by a $271 billion backlog and multi-year contracts, driving consistent revenue growth of 10% in 2025 and 9% in Q1 2026. Earnings gro…
Thermo Fisher Scientific Inc. operates in the healthcare sector, specializing in medical diagnostics and research tools across four main segments: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company demonstrates medium business quality with steady revenue growth of 6.2% and earnings growth of 9.6% in the most recent q…
Accumulation Zones
| Metric |
RTX |
TMO |
| Zone Low |
$102.04 |
$381.90 |
| Zone High |
$115.64 |
$432.82 |
| In Buy Zone? |
No
|
No
|